1stOncology™: Cancer Intelligence Service – Page 3880 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

On December 18, 2023 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 (Press release, Regeneron, DEC 18, 2023, View Source [SID1234638652]). The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron’s website at View Source A replay and transcript of the webcast will be archived on the Company’s website for at least 30 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

On December 18, 2023 Propanc Biopharma, Inc. (OTC Pink: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, reported that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors (Press release, Propanc, DEC 18, 2023, View Source [SID1234638651]). Funds will also be utilized to advance the Company’s back up clinical candidate, Rec-PRP, a synthetic recombinant version of PRP, which will further enhance the potency and stability of the naturally derived proenzyme treatment. As part of the process, the opportunity to consider up-listing to a national US stock exchange will also be considered. The emerging boutique advisory firm currently has a $3B+ transaction history and access to a global network of investors the Company intends to fully utilize.

PRP, a combination of two proenzymes trypsinogen and chymotrypsinogen, is a novel, targeted therapy for the treatment and prevention of metastatic cancer. Scientific evidence has shown potent effects against cancer stem cells, inducing these cells to differentiate (transform) into a less malignant, or dormant state, thus rendering them benign. Cancer stems cells represent the final frontier, as they are responsible for metastasis and invasion, causing the cancer to return and spread. They also eventually become resistant to standard treatment options like chemotherapy, where PRP has shown to be effective against chemoresistant pancreatic cancer cells, where patients suffer from a high mortality rate.

"PRP represents an exciting and novel method to control the threat of resistant tumors, which, if left untreated, can ultimately lead to patient death," said James Nathanielsz, Propanc’s Chief Executive Officer. "Importantly, PRP targets cancer stem cells, but leaves healthy stem cells alone. This means it is less toxic than standard treatments. We believe PRP could become a welcome addition to the treatment process for many aggressive cancer types, like pancreatic and ovarian cancers, where patient prognosis is often poor when left diagnosed. Therefore, we are offering an attractive investment opportunity to become involved in the development of a novel, first-in-class cancer therapy that as we progress further down the clinical development pathway, we believe has the potential to become a highly sought after strategic asset to the oncology portfolio of a global pharmaceutical, biotech, or mid-tier specialty company, serious about treating this killer disease."

Philogen to attend the ESMO TAT congress in Paris on February 26-28, 2024

On December 18, 2023 Philogen reported that Prof. Dr. Giuseppe Curigliano, is giving a presentation about the Phase I DODEKA study on February 26th, entitled "Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors" (Press release, Philogen, DEC 18, 2023, https://www.philogen.com/2023/12/18/philogen-to-attend-the-esmo-tat-congress-in-paris-on-february-26-28-2024/ [SID1234638650]).

Dr. Jacqueline Mock is presenting a poster about Philochem’s new small molecule drug conjugate on February 26th, entitled "Optimisation of FAP-targeted small molecule drug conjugates for the delivery and release of cytotoxic payloads in solid tumors"

Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma

On December 18, 2023 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, reported that US WorldMeds1 (USWM), a Kentucky-based specialty pharmaceutical company to whom it divested certain assets in its eflornithine pediatric neuroblastoma program, received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients who have achieved at least a partial response to certain prior therapies (Press release, Panbela Therapeutics, DEC 18, 2023, View Source;utm_medium=rss&utm_campaign=panbela-therapeutics-announces-us-worldmeds-nda-approval-for-eflornithine-dfmo-in-pediatric-neuroblastoma [SID1234638649]).

The approval of USWM’s NDA for the use of eflornithine for the treatment of patients with high-risk neuroblastoma marks the first FDA approval of an NDA for any polyamine targeted therapy in a cancer indication. "This approval highlights the role polyamines can play in cancer therapy as we look forward to data from our ongoing programs in metastatic pancreatic cancer, colorectal cancer, non-small cell lung cancer, and prostate cancer and the advancement of preclinical programs in ovarian and multiple myeloma," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.

In July 2023, Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5 million of non-dilutive funding, including payments upon USWM’s successful completion of milestones related to eflornithine’s clinical development, regulatory approval, and commercial sales. "The FDA’s approval of USWM’s eflornithine NDA for high-risk neuroblastoma is an exciting milestone in our partnership. This demonstrates the potential for polyamine targeted therapies in cancer," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.

"This approval is a prerequisite for considerable development milestone payments for Panbela as US WorldMeds continues its efforts to bring eflornithine to the market." "After many years investigating the role of polyamines and the therapeutic potential of eflornithine in neuroblastoma, it is rewarding to see USWM’s success with the FDA’s positive review of its NDA for eflornithine," said Elizabeth Bruckheimer, Ph.D., Vice President & Chief Scientific Officer of Panbela, "We are excited about how the USWM NDA approval of eflornithine should help address this high unmet need in patients with neuroblastoma."

Neuroblastoma, a rare cancer originating from immature nerve cells, contributes to nearly 15% of pediatric cancer deaths.[1] Panbela’s subsidiary, Cancer Prevention Pharmaceuticals, extensively collaborated with leading neuroblastoma research groups such as the Neuroblastoma Medulloblastoma Translational Research Consortium (NMTRC) (now Beat Childhood Cancer), New Advances in Neuroblastoma Therapy (NANT), the Children’s Oncology Group (COG), and the National Cancer Institute (NCI) in the clinical development of eflornithine as a treatment for neuroblastoma before the program was divested to USWM.

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors

On December 18, 2023 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, reported an antibody evaluation, option and license agreement with Ona Therapeutics ("Ona"), a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer (Press release, Ona Therapeutics, DEC 18, 2023, View Source;utm_medium=rss&utm_campaign=biocytogen-enters-into-antibody-agreement-with-ona-therapeutics-to-develop-antibody-drug-conjugates-targeting-solid-tumors [SID1234638648]).

Under the terms of the agreement, Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for antibody-drug conjugate (ADC) development, manufacturing and commercialization in mutually agreed indications and territories.

Biocytogen will receive an upfront payment for granting the option, and will be further entitled to an option-exercise fee, development and commercialization milestone payments, as well as single-digit royalties on net sales once Ona elects to exercise the option in full.

Dr. Yuelei Shen, President and CEO of Biocytogen, said: "As part of Project Integrum, Biocytogen has been discovering fully human antibodies against 200 TAA targets based on their internalization activity. We are honored that Ona, among other global biopharmaceutical companies, recognizes the potential of our proprietary off-the-shelf antibodies. We believe Ona’s deep understanding of novel mechanisms of resistance in advanced cancer and their capabilities in ADC design and development will accelerate the development of our antibodies into promising therapeutics."

Dr. Valerie Vanhooren, CEO & co-founder of Ona, said: "We look forward to evaluating Biocytogen’s proprietary antibodies for ADC uses. We believe the combination of Biocytogen’s rich antibody repertoire with Ona’s unique insight in advanced cancer biology will have great advantages in the discovering and developing of first-in-class molecules for unmet medical needs."